leadf
logo-loader
viewBioPorto

BioPorto Diagnostics reveals progress on its co-developed 10-minute coronavirus test

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive its fast-track collaboration with the University of Southern Denmark (SDU) to create a 10-minute test for the coronavirus (COVID-19) has yielded promising results in tests against heat-inactivated virus. Eriksen says in the coming weeks the group plans to perfect the test using different sample types from known-positive patients. If successful, the company intends to request an Emergency Use Authorization from the FDA and to apply for a CE Mark in Europe.

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

BioPorto reveals another quarter of strong revenue from sales of its NGAL...

BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive the group's second quarter results revealed strong revenue growth from sales of its NGAL kidney damage test in a period defined by the coronavirus pandemic which it is also involved in the fight against. Eriksen said sales of the...

on 08/25/2020

2 min read